US EditionJenaValve’s Trilogy THV Evaluated in Expanded Cohort of ALIGN-AR Pivotal Trial - Cardiac Interventions Today
Summary by Cardiac Interventions Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
JenaValve’s Trilogy THV Evaluated in Expanded Cohort of ALIGN-AR Pivotal Trial - Cardiac Interventions Today
April 7, 2025—JenaValve Technology, Inc. recently announced results from the expanded cohort of 500 patients in the ALIGN-AR pivotal trial. ALIGN-AR is evaluating the company’s Trilogy transcatheter heart valve (THV) system in high-risk patients with symptomatic, severe aortic regurgitation (AR). According to the company, the late-breaking clinical trial results underscore the safety and efficacy of the Trilogy THV system in high surgical-risk p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
